Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?

Progress in Retinal and Eye Research

Volumn 40, Issue , 2014, Pages 16-34

  Pennock, Steven ^a   Haddock, Luis J ^a   Eliott, Dean ^a   Mukai, Shizuo ^a   Kazlauskas, Andrius ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Growth factors; PDGFR; Proliferative vitreoretinopathy; Retinal detachment; Signaling; Vitreous

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; DAUNORUBICIN; DECORIN; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NEUTRALIZING ANTIBODY; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR C; PLATELET DERIVED GROWTH FACTOR C ANTIBODY; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; RECOMBINANT GROWTH FACTOR; SILICONE OIL; STEROID; TRANSFORMING GROWTH FACTOR BETA; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; SIGNAL PEPTIDE;

ADJUVANT THERAPY; BASIC RESEARCH; BIOLOGICAL ACTIVITY; CELL AGGREGATION; CELL MIGRATION; CELL TYPE; CHOROID DETACHMENT; CLINICAL TRIAL (TOPIC); CRYOTHERAPY; CYTOKINE PRODUCTION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; FIBROBLAST; GENE THERAPY; GLIA CELL; HUMAN; MEDIATOR; MUELLER CELL; NONHUMAN; PATHOGENESIS; PIGMENT EPITHELIUM; POSTOPERATIVE INFLAMMATION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; RABBIT; RETINA SURGERY; RETINECTOMY; REVIEW; RISK FACTOR; SCLERAL BUCKLE; STEROID THERAPY; SURGICAL APPROACH; UVEITIS; VISUAL ACUITY; VITRECTOMY; VITREORETINAL SURGERY; VITREORETINOPATHY; VITREOUS BODY; VITREOUS HEMORRHAGE; METABOLISM; PHYSIOLOGY; VITREORETINOPATHY, PROLIFERATIVE;

HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RISK FACTORS; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 84899048922     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2013.12.006     Document Type: Review

References (179)

1. Aaberg T.M. Surgery as the primary management of proliferative vitreoretinopathy: a history reflecting my experiences and biases. Arch. Ophthalmol. 2010, 128:1068-1070.
2. Abe J., Takahashi M., Ishida M., Lee J.D., Berk B.C. c-Src is required for oxidative stress-mediated activation of big mitogen-activated protein kinase 1. J.Biol. Chem. 1997, 272:20389-20394.
3. Abrams G.W., Azen S.P., McCuen B.W., Flynn H.W., Lai M.Y., Ryan S.J. Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11. Arch. Ophthalmol. 1997, 115:335-344.
4. Agrawal R.N., He S., Spee C., Cui J.Z., Ryan S.J., Hinton D.R. Invivo models of proliferative vitreoretinopathy. Nat. Protoc. 2007, 2:67-77.
5. Ahmadieh H., Feghhi M., Tabatabaei H., Shoeibi N., Ramezani A., Mohebbi M.R. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmology 2008, 115:1938-1943.
6. Akiyama H., Kachi S., Silva R.L., Umeda N., Hackett S.F., McCauley D., McCauley T., Zoltoski A., Epstein D.M., Campochiaro P.A. Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies. J.Cell. Physiol. 2006, 207:407-412.
7. Anderson D.H., Stern W.H., Fisher S.K., Erickson P.A., Borgula G.A. The onset of pigment epithelial proliferation after retinal detachment. Investig. Ophthalmol. Vis. Sci. 1981, 21:10-16.
8. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008, 22:1276-1312.
9. Andrews A., Balciunaite E., Leong F.L., Tallquist M., Soriano P., Refojo M., Kazlauskas A. Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy. Investig. Ophthalmol. Vis. Sci. 1999, 40:2683-2689.
10. Antoniu S.A. Targeting RhoA/ROCK pathway in pulmonary arterial hypertension. Expert Opin. Ther. Targets 2012, 16:355-363.
11. Asaria R.H., Kon C.H., Bunce C., Charteris D.G., Wong D., Khaw P.T., Aylward G.W. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology 2001, 108:1179-1183.
12. Asaria R.H., Kon C.H., Bunce C., Sethi C.S., Limb G.A., Khaw P.T., Aylward G.W., Charteris D.G. Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid. Br. J. Ophthalmol. 2004, 88:1439-1442.
13. Asato R., Yoshida S., Ogura A., Nakama T., Ishikawa K., Nakao S., Sassa Y., Enaida H., Oshima Y., Ikeo K., Gojobori T., Kono T., Ishibashi T. Comparison of gene expression profile of epiretinal membranes obtained from eyes with proliferative vitreoretinopathy to that of secondary epiretinal membranes. PLoS one 2013, 8:e54191.
14. Ball S.G., Shuttleworth C.A., Kielty C.M. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J.Cell. Biol. 2007, 177:489-500.
15. Banerjee S., Savant V., Scott R.A., Curnow S.J., Wallace G.R., Murray P.I. Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Investig. Ophthalmol. Vis. Sci. 2007, 48:2203-2207.
16. Baroni S.S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., Fraticelli P., Sambo P., Funaro A., Kazlauskas A., Avvedimento E.V., Gabrielli A. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N.Engl. J. Med. 2006, 354:2667-2676.
17. Bastiaans J., van Meurs J.C., van Holten-Neelen C., Nagtzaam N., van Hagen P.M., Chambers R.C., Hooijkaas H., Dik W.A. Thrombin induces epithelial-mesenchymal transition and collagen production by retinal pigment epithelial cells via autocrine PDGF-receptor signaling. Investig. Ophthalmol. Vis. Sci. 2013, 54:8306-8314.
18. Battegay E.J., Raines E.W., Seifert R.A., Bowen-Pope D.F., Ross R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990, 63:515-524.
19. Baudouin C., Fredj-Reygrobellet D., Gordon W.C., Baudouin F., Peyman G., Lapalus P., Gastaud P., Bazan N.G. Immunohistologic study of epiretinal membranes in proliferative vitreoretinopathy. Am. J. Ophthalmol. 1990, 110:593-598.
20. Baudouin C., Fredj-Reygrobellet D., Brignole F., Negre F., Lapalus P., Gastaud P. Growth factors in vitreous and subretinal fluid cells from patients with proliferative vitreoretinopathy. Ophthalmic Res. 1993, 25:52-59.
21. Bergsten E., Uutela M., Li X., Pietras K., Ostman A., Heldin C.H., Alitalo K., Eriksson U. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat. Cell. Biol. 2001, 3:512-516.
22. Bochaton-Piallat M.L., Kapetanios A.D., Donati G., Redard M., Gabbiani G., Pournaras C.J. TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Investig. Ophthalmol. Vis. Sci. 2000, 41:2336-2342.
23. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., Bargonetti J., Bartel F., Taubert H., Wuerl P., Onel K., Yip L., Hwang S.J., Strong L.C., Lozano G., Levine A.J. Asingle nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.
24. Bonnet M., Fleury J., Guenoun S., Yaniali A., Dumas C., Hajjar C. Cryopexy in primary rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy?. Graefes Arch. Clin. Exp. Ophthalmol. 1996, 234:739-743.
25. Campochiaro P.A., Sugg R., Grotendorst G., Hjelmeland L.M. Retinal pigment epithelial cells produce PDGF-like proteins and secrete them into their media. Exp. Eye Res. 1989, 49:217-227.
26. Campochiaro P.A., Hackett S.F., Vinores S.A. Growth factors in the retina and retinal pigmented epithelium. Prog. Retin. Eye Res. 1996, 547-567. Elsevier Science Ltd.
27. Cardillo J.A., Stout J.T., LaBree L., Azen S.P., Omphroy L., Cui J.Z., Kimura H., Hinton D.R., Ryan S.J. Post-traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology 1997, 104:1166-1173.
28. Carrington L., McLeod D., Boulton M. IL-10 and antibodies to TGF-beta2 and PDGF inhibit RPE-mediated retinal contraction. Investig. Ophthalmol. Vis. Sci. 2000, 41:1210-1216.
29. Casaroli-Marano R.P., Pagan R., Vilaro S. Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells. Investig. Ophthalmol. Vis. Sci. 1999, 40:2062-2072.
30. Cassidy L., Barry P., Shaw C., Duffy J., Kennedy S. Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders. Br. J. Ophthalmol. 1998, 82:181-185.
31. Chan C.M., Fang J.Y., Lin H.H., Yang C.Y., Hung C.F. Lycopene inhibits PDGF-BB-induced retinal pigment epithelial cell migration by suppression of PI3K/Akt and MAPK pathways. Biochem. Biophys. Res. Commun. 2009, 388:172-176.
32. Chan C.M., Huang J.H., Chiang H.S., Wu W.B., Lin H.H., Hong J.Y., Hung C.F. Effects of (-)-epigallocatechin gallate on RPE cell migration and adhesion. Mol. Vis. 2010, 16:586-595.
33. Chan C.M., Chang H.H., Wang V.C., Huang C.L., Hung C.F. Inhibitory effects of resveratrol on PDGF-BB-induced retinal pigment epithelial cell migration via PDGFRbeta, PI3K/Akt and MAPK pathways. PLoS one 2013, 8:e56819.
34. Charteris D.G., Aylward G.W., Wong D., Groenewald C., Asaria R.H., Bunce C. Arandomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 2004, 111:2240-2245.
35. Choudhury P., Chen W., Hunt R.C. Production of platelet-derived growth factor by interleukin-1β and transforming growth factor-β-stimulated retinal pigment epithelial cells leads to contraction of collagen gels. Investig. Ophthalmol. Vis. Sci. 1997, 38:824-833.
36. Coll G.E., Chang S., Sun J., Wieland M.R., Berrocal M.H. Perfluorocarbon liquid in the management of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1995, 102:630-638. discussion 638-639.
37. Committee T.R.S.T. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983, 90:121-125.
38. Connor T.B., Roberts A.B., Sporn M.B., Danielpour D., Dart L.L., Michels R.G., de Bustros S., Enger C., Kato H., Lansing M., et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J.Clin. Investig. 1989, 83:1661-1666.
39. Cowley M., Conway B.P., Campochiaro P.A., Kaiser D., Gaskin H. Clinical risk factors for proliferative vitreoretinopathy. Arch. Ophthalmol. 1989, 107:1147-1151.
40. Cui J.Z., Chiu A., Maberley D., Ma P., Samad A., Matsubara J.A. Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye 2007, 21:200-208.
41. Cui J., Lei H., Samad A., Basavanthappa S., Maberley D., Matsubara J., Kazlauskas A. PDGF receptors are activated in human epiretinal membranes. Exp. Eye Res. 2009, 88:438-444.
42. Del Vecchio P.J., Bizios R., Holleran L.A., Judge T.K., Pinto G.L. Inhibition of human scleral fibroblast proliferation with heparin. Investig. Ophthalmol. Vis. Sci. 1988, 29:1272-1276.
43. Dieudonne S.C., La Heij E.C., Diederen R., Kessels A.G., Liem A.T., Kijlstra A., Hendrikse F. High TGF-beta2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy. Investig. Ophthalmol. Vis. Sci. 2004, 45:4113-4118.
44. Dolloff N.G., Russell M.R., Loizos N., Fatatis A. Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor. Cancer Res. 2007, 67:555-562.
45. Dumont P., Leu J.I., Della Pietra A.C., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 2003, 33:357-365.
46. Duquesne N., Bonnet M., Adeleine P. Preoperative vitreous hemorrhage associated with rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy?. Graefes Arch. Clin. Exp. Ophthalmol. 1996, 234:677-682.
47. El-Ghrably I.A., Dua H.S., Orr G.M., Fischer D., Tighe P.J. Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br. J. Ophthalmol. 2001, 85:461-470.
48. Elner S.G., Elner V.M., Jaffe G.J., Stuart A., Kunkel S.L., Strieter R.M. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr. Eye Res. 1995, 14:1045-1053.
49. Evren O., Turgut B., Celiker U., Ates K. The impact of octreotide in experimental proliferative vitreoretinopathy. Indian J. Ophthalmol. 2013, 61:109-114.
50. Fastenberg D.M., Diddie K.R., Dorey K., Ryan S.J. The role of cellular proliferation in an experimental model of massive periretinal proliferation. Am. J. Ophthalmol. 1982, 93:565-572.
51. Fastenberg D.M., Diddie K.R., Sorgente N., Ryan S.J. Acomparison of different cellular inocula in an experimental model of massive periretinal proliferation. Am. J. Ophthalmol. 1982, 93:559-564.
52. Feist R.M., King J.L., Morris R., Witherspoon C.D., Guidry C. Myofibroblast and extracellular matrix origins in proliferative vitreoretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2013.
53. Fisher S.K., Lewis G.P. Muller cell and neuronal remodeling in retinal detachment and reattachment and their potential consequences for visual recovery: a review and reconsideration of recent data. Vis. Res. 2003, 43:887-897.
54. Fredriksson L., Li H., Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004, 15:197-204.
55. Frisch S.M., Ruoslahti E. Integrins and anoikis. Curr. Opin. Cell. Biol. 1997, 9:701-706.
56. Gamulescu M.A., Chen Y., He S., Spee C., Jin M., Ryan S.J., Hinton D.R. Transforming growth factor beta2-induced myofibroblastic differentiation of human retinal pigment epithelial cells: regulation by extracellular matrix proteins and hepatocyte growth factor. Exp. Eye Res. 2006, 83:212-222.
57. Garweg J.G., Tappeiner C., Halberstadt M. Pathophysiology of proliferative vitreoretinopathy in retinal detachment. Surv. Ophthalmol. 2013, 58:321-329.
58. Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O., Hofstrand P.D., Gao Z., Shoemaker K., Bukowski T.R., Moore M., Feldhaus A.L., Humes J.M., Palmer T.E., Hart C.E. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J.Biol. Chem. 2001, 276:27406-27414.
59. Gillan L., Matei D., Fishman D.A., Gerbin C.S., Karlan B.Y., Chang D.D. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 2002, 62:5358-5364.
60. Girard P., Mimoun G., Karpouzas I., Montefiore G. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina 1994, 14:417-424.
61. Hansen K., Johnell M., Siegbahn A., Rorsman C., Engstrom U., Wernstedt C., Heldin C.H., Ronnstrand L. Mutation of a Src phosphorylation site in the PDGF beta-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis. EMBO J. 1996, 15:5299-5313.
62. Harada C., Mitamura Y., Harada T. The role of cytokines and trophic factors in epiretinal membranes: involvement of signal transduction in glial cells. Prog. Retin. Eye Res. 2006, 25:149-164.
63. Hardwick J.S., Sefton B.M. Activation of the Lck tyrosine protein kinase by hydrogen peroxide requires the phosphorylation of Tyr-394. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:4527-4531.
64. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
65. He S., Chen Y., Khankan R., Barron E., Burton R., Zhu D., Ryan S.J., Oliver N., Hinton D.R. Connective tissue growth factor as a mediator of intraocular fibrosis. Investig. Ophthalmol. Vis. Sci. 2008, 49:4078-4088.
66. Heeneman S., Haendeler J., Saito Y., Ishida M., Berk B.C. Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor. Key role for the p66 adaptor protein Shc. J.Biol. Chem. 2000, 275:15926-15932.
67. Heldin C.-H., Westermark B. Platelet-derived growth factor: mechanism of action and possible invivo function. Cell. Regul. 1990, 1:555-566.
68. Herrlich A., Daub H., Knebel A., Herrlich P., Ullrich A., Schultz G., Gudermann T. Ligand-independent activation of platelet-derived growth factor receptor is a necessary intermediate in lysophosphatidic, acid-stimulated mitogenic activity in L cells. Proc. Natl. Acad. Sci. 1998, 95:8985-8990.
69. Hinton D.R., He S., Jin M.L., Barron E., Ryan S.J. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye 2002, 16:422-428.
70. Hoeg J.M., Brewer H.B. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA: J. Am. Med. Assoc. 1987, 258:3532-3536.
71. Hoffmann S., He S., Jin M., Ehren M., Wiedemann P., Ryan S.J., Hinton D.R. Aselective cyclic integrin antagonist blocks the integrin receptors alphavbeta3 and alphavbeta5 and inhibits retinal pigment epithelium cell attachment, migration and invasion. BMC Ophthalmol. 2005, 5:16.
72. Iandiev I., Uckermann O., Pannicke T., Wurm A., Tenckhoff S., Pietsch U.C., Reichenbach A., Wiedemann P., Bringmann A., Uhlmann S. Glial cell reactivity in a porcine model of retinal detachment. Investig. Ophthalmol. Vis. Sci. 2006, 47:2161-2171.
73. Ikuno Y., Kazlauskas A. An invivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor. Investig. Ophthalmol. Vis. Sci. 2002, 43:2406-2411.
74. Ikuno Y., Kazlauskas A. TGFbeta1-dependent contraction of fibroblasts is mediated by the PDGFalpha receptor. Investig. Ophthalmol. Vis. Sci. 2002, 43:41-46.
75. Ikuno Y., Leong F.L., Kazlauskas A. Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor. Investig. Ophthalmol. Vis. Sci. 2000, 41:3107-3116.
76. Ikuno Y., Leong F.L., Kazlauskas A. PI3K and PLCgamma play a central role in experimental PVR. Investig. Ophthalmol. Vis. Sci. 2002, 43:483-489.
77. Ishikawa K., Yoshida S., Nakao S., Nakama T., Kita T., Asato R., Sassa Y., Arita R., Miyazaki M., Enaida H., Oshima Y., Murakami N., Niiro H., Ono J., Matsuda A., Goto Y., Akashi K., Izuhara K., Kudo A., Kono T., Hafezi-Moghadam A., Ishibashi T. Periostin promotes the generation of fibrous membranes in proliferative vitreoretinopathy. FASEB J 2014, 28:131-142.
78. Ito S., Sakamoto T., Tahara Y., Goto Y., Akazawa K., Ishibashi T., Inomata H. The effect of tranilast on experimental proliferative vitreoretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 1999, 237:691-696.
79. Johnsen E.O., Froen R.C., Albert R., Omdal B.K., Sarang Z., Berta A., Nicolaissen B., Petrovski G., Moe M.C. Activation of neural progenitor cells in human eyes with proliferative vitreoretinopathy. Exp. Eye Res. 2012, 98:28-36.
80. Kawahara S., Hata Y., Kita T., Arita R., Miura M., Nakao S., Mochizuki Y., Enaida H., Kagimoto T., Goto Y., Hafezi-Moghadam A., Ishibashi T. Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins. Diabetes 2008, 57:2784-2793.
81. Khankan R., Oliver N., He S., Ryan S.J., Hinton D.R. Regulation of fibronectin-EDA through CTGF domain-specific interactions with TGFbeta2 and its receptor TGFbetaRII. Investig. Ophthalmol. Vis. Sci. 2011, 52:5068-5078.
82. Kiilgaard J.F., Prause J.U., Prause M., Scherfig E., Nissen M.H., la Cour M. Subretinal posterior pole injury induces selective proliferation of RPE cells in the periphery in invivo studies in pigs. Investig. Ophthalmol. Vis. Sci. 2007, 48:355-360.
83. Kimoto K., Nakatsuka K., Matsuo N., Yoshioka H. p38 MAPK mediates the expression of type I collagen induced by TGF-beta 2 in human retinal pigment epithelial cells ARPE-19. Investig. Ophthalmol. Vis. Sci. 2004, 45:2431-2437.
84. Kita T., Hata Y., Kano K., Miura M., Nakao S., Noda Y., Shimokawa H., Ishibashi T. Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor. Diabetes 2007, 56:231-238.
85. Kita T., Hata Y., Miura M., Kawahara S., Nakao S., Ishibashi T. Functional characteristics of connective tissue growth factor on vitreoretinal cells. Diabetes 2007, 56:1421-1428.
86. Kita T., Hata Y., Arita R., Kawahara S., Miura M., Nakao S., Mochizuki Y., Enaida H., Goto Y., Shimokawa H., Hafezi-Moghadam A., Ishibashi T. Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17504-17509.
87. Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 2011, 437:169-183.
88. Kon C.H., Occleston N.L., Aylward G.W., Khaw P.T. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Investig. Ophthalmol. Vis. Sci. 1999, 40:705-712.
89. La Heij E.C., van de Waarenburg M.P., Blaauwgeers H.G., Kessels A.G., Liem A.T., Theunissen C., Steinbusch H., Hendrikse F. Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. Am. J. Ophthalmol. 2002, 134:367-375.
90. Lashkari K., Rahimi N., Kazlauskas A. Hepatocyte growth factor receptor in human RPE cells: implications in proliferative vitreoretinopathy. Investig. Ophthalmol. Vis. Sci. 1999, 40:149-156.
91. Lei H., Kazlauskas A. Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. J.Biol. Chem. 2009, 284:6329-6336.
92. Lei H., Kazlauskas A. Areactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor alpha. Mol. Cell. Biol. 2014, 34:110-122.
93. Lei H., Hovland P., Velez G., Haran A., Gilbertson D., Hirose T., Kazlauskas A. Apotential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy. Investig. Ophthalmol. Vis. Sci. 2007, 48:2335-2342.
94. Lei H., Velez G., Hovland P., Hirose T., Kazlauskas A. Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy. Investig. Ophthalmol. Vis. Sci. 2008, 49:42-48.
95. Lei H., Velez G., Hovland P., Hirose T., Gilbertson D., Kazlauskas A. Growth factors outside the PDGF family drive experimental PVR. Investig. Ophthalmol. Vis. Sci. 2009, 50:3394-3403.
96. Lei H., Rheaume M.A., Kazlauskas A. Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp. Eye Res. 2010, 90:376-381.
97. Lei H., Velez G., Cui J., Samad A., Maberley D., Matsubara J., Kazlauskas A. N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am. J. Pathol. 2010, 177:132-140.
98. Lei H., Rheaume M.A., Velez G., Mukai S., Kazlauskas A. Expression of PDGFR{alpha} is a determinant of the PVR potential of ARPE19 cells. Investig. Ophthalmol. Vis. Sci. 2011, 52:5016-5021.
99. Lei H., Velez G., Kazlauskas A. Pathological signaling via platelet-derived growth factor receptor {alpha} involves chronic activation of Akt and suppression of p53. Mol. Cell. Biol. 2011, 31:1788-1799.
100. Lei H., Rheaume M.A., Cui J., Mukai S., Maberley D., Samad A., Matsubara J., Kazlauskas A. Anovel function of p53: a gatekeeper of retinal detachment. Am. J. Pathol. 2012, 181:866-874.
101. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
102. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 2009, 9:749-758.
103. Lewis G.P., Charteris D.G., Sethi C.S., Leitner W.P., Linberg K.A., Fisher S.K. The ability of rapid retinal reattachment to stop or reverse the cellular and molecular events initiated by detachment. Investig. Ophthalmol. Vis. Sci. 2002, 43:2412-2420.
104. Li X., Ponten A., Aase K., Karlsson L., Abramsson A., Uutela M., Backstrom G., Hellstrom M., Bostrom H., Li H., Soriano P., Betsholtz C., Heldin C.H., Alitalo K., Ostman A., Eriksson U. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor [see comments]. Nat. Cell. Biol. 2000, 2:302-309.
105. Linseman D.A., Benjamin C.W., Jones D.A. Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J.Biol. Chem. 1995, 270:12563-12568.
106. Liou G.I., Pakalnis V.A., Matragoon S., Samuel S., Behzadian M.A., Baker J., Khalil I.E., Roon P., Caldwell R.B., Hunt R.C., Marcus D.M. HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR. Mol. Vis. 2002, 8:494-501.
107. Liu Y., Li M., Warburton R.R., Hill N.S., Fanburg B.L. The 5-HT transporter transactivates the PDGFbeta receptor in pulmonary artery smooth muscle cells. FASEB J. 2007, 21:2725-2734.
108. Lleo Perez A., Campos Fernandez R., Lopez Santovena F., Sanchez Lorente G., Hernandez Martinez F.J., Navarro Palop C. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Arch. Soc. Esp. Oftalmol. 2000, 75:741-750.
109. Machemer R., Aaberg T.M., Freeman H.M., Irvine A.R., Lean J.S., Michels R.M. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am. J. Ophthalmol. 1991, 112:159.
110. Majack R.A., Majesky M.W., Goodman L.V. Role of PDGF-A expression in the control of vascular smooth muscle cell growth by transforming growth factor-beta. J.Cell. Biol. 1990, 111:239-247.
111. Matsui T., Heidaran M., Miki T., Popescu N., LaRochelle W., Kraus M., Pierce J., Aaronson S. Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science 1989, 243:800-804.
112. Matsui T., Pierce J.H., Fleming T.P., Greenberger J.S., LaRochelle W.J., Ruggiero M., Aaronson S.A. Independent expression of human α or β platelet-derived growth factor receptor cDNAs in a naive hematopoietic cell leads to functional coupling with mitogenic and chemotactic signaling pathways. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:8314-8318.
113. Matsumoto T., Claesson-Welsh L. VEGF receptor signal transduction. Sci. STKE 2001, 2001:RE21.
114. Medearis S., Han I.C., Huang J.K., Yang P., Jaffe G.J. The role of Bcl-xL in mouse RPE cell survival. Investig. Ophthalmol. Vis. Sci. 2011, 52:6545-6551.
115. Michels R.G. Surgery of retinal detachment with proliferative vitreoretinopathy. Retina 1984, 4:63-83.
116. Mishra R.K., Alokam R., Sriram D., Yogeeswari P. Potential role of Rho kinase inhibitors in combating diabetes-related complications including diabetic neuropathy-a review. Curr. Diabetes Rev. 2013, 9:249-266.
117. Morales S.A., Mareninov S., Prasad P., Wadehra M., Braun J., Gordon L.K. Collagen gel contraction by ARPE-19 cells is mediated by a FAK-Src dependent pathway. Exp. Eye Res. 2007, 85:790-798.
118. Morales S.A., Mareninov S., Coulam P., Wadehra M., Goodglick L., Braun J., Gordon L.K. Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2). Investig. Ophthalmol. Vis. Sci. 2009, 50:4949-4956.
119. Morales S.A., Mareninov S., Wadehra M., Zhang L., Goodglick L., Braun J., Gordon L.K. FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction. Investig. Ophthalmol. Vis. Sci. 2009, 50:462-469.
120. Morales S.A., Telander D.G., Mareninov S., Nagy A., Wadehra M., Braun J., Gordon L.K. Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells. Exp. Eye Res. 2012, 102:10-16.
121. Morescalchi F., Duse S., Gambicorti E., Romano M.R., Costagliola C., Semeraro F. Proliferative vitreoretinopathy after eye injuries: an overexpression of growth factors and cytokines leading to a retinal keloid. Mediat. Inflamm. 2013, 2013:269787.
122. Moysidis S.N., Thanos A., Vavvas D.G. Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Mediat. Inflamm. 2012, 2012:815937.
123. Mukherjee S., Guidry C. The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation. Investig. Ophthalmol. Vis. Sci. 2007, 48:1892-1899.
124. Muller Y.A., Christinger H.W., Keyt B.A., de Vos A.M. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Structure 1997, 5:1325-1338.
125. Muller Y.A., Li B., Christinger H.W., Wells J.A., Cunningham B.C., de Vos A.M. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:7192-7197.
126. Nassar K., Luke J., Luke M., Kamal M., Abd El-Nabi E., Soliman M., Rohrbach M., Grisanti S. The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR). Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249:1649-1660.
127. Oefner C., D'Arcy A., Winkler F.K., Eggimann B., Hosang M. Crystal structure of human platelet-derived growth factor BB. EMBO J. 1992, 11:3921-3926.
128. Olson L.E., Soriano P. Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis. Dev. Cell 2009, 16:303-313.
129. Oshima Y., Sakamoto T., Hisatomi T., Tsutsumi C., Ueno H., Ishibashi T. Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy. Gene Ther. 2002, 9:1214-1220.
130. Pastor-Idoate S., Rodriguez-Hernandez I., Rojas J., Fernandez I., Garcia-Gutierrez M.T., Ruiz-Moreno J.M., Rocha-Sousa A., Ramkissoon Y., Harsum S., Maclaren R.E., Charteris D., van Meurs J., Gonzalez-Sarmiento R., Pastor J.C. The p53 codon 72 polymorphism (rs1042522) is associated with proliferative vitreoretinopathy: the Retina 4 Project. Ophthalmology 2013, 120:623-628.
131. Pastor-Idoate S., Rodriguez-Hernandez I., Rojas J., Fernandez I., Garcia-Gutierrez M.T., Ruiz-Moreno J.M., Rocha-Sousa A., Ramkissoon Y., Harsum S., Maclaren R.E., Charteris D., Vanmeurs J.C., Gonzalez-Sarmiento R., Pastor J.C. The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathy. PloS One 2013, 8:e82283.
132. Pennock S., Kazlauskas A. Vascular endothelial growth factor a competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses. Mol. Cell. Biol. 2012, 32:1955-1966.
133. Pennock S., Rheaume M.A., Mukai S., Kazlauskas A. Anovel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy. Am. J. Pathol. 2011, 179:2931-2940.
134. Pennock S., Kim D., Mukai S., Kuhnle M., Chun D.W., Matsubara J., Cui J., Ma P., Maberley D., Samad A., Van Geest R.J., Lesnik Oberstein S., Schlingemann R.O., Kazlauskas A. Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease. Am. J. Pathol 2013, 182:1659-1670.
135. Prenzel N., Zwick E., Daub H., Leserer M., Abraham R., Wallasch C., Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999, 402:884-888.
136. Raines E.W., Ross R. Purification of human platelet-derived growth factor. Methods Enzymol. 1985, 109:749-773.
137. Reichel M.B., Ali R.R., D'Esposito F., Clarke A.R., Luthert P.J., Bhattacharya S.S., Hunt D.M. High frequency of persistent hyperplastic primary vitreous and cataracts in p53-deficient mice. Cell. Death Differ. 1998, 5:156-162.
138. Reigstad L.J., Varhaug J.E., Lillehaug J.R. Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J. 2005, 272:5723-5741.
139. Ricker L.J., Kijlstra A., Kessels A.G., de Jager W., Liem A.T., Hendrikse F., La Heij E.C. Interleukin and growth factor levels in subretinal fluid in rhegmatogenous retinal detachment: a case-control study. PLoS one 2011, 6:e19141.
140. Robbins S.G., Mixon R.N., Wilson D.J., Hart C.E., Robertson J.E., Westra I., Planck S.R., Rosenbaum J.T. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Investig. Ophthalmol. Vis. Sci. 1994, 35(10):3649-3663.
141. Rojas J., Fernandez I., Pastor J.C., Garcia-Gutierrez M.T., Sanabria R.M., Brion M., Sobrino B., Manzanas L., Giraldo A., Rodriguez-de la Rua E., Carracedo A. Development of predictive models of proliferative vitreoretinopathy based on genetic variables: the Retina 4 project. Investig. Ophthalmol. Vis. Sci. 2009, 50:2384-2390.
142. Rojas J., Fernandez I., Pastor J.C., Garcia-Gutierrez M.T., Sanabria M.R., Brion M., Coco R.M., Ruiz-Moreno J.M., Garcia-Arumi J., Elizalde J., Ruiz-Miguel M., Gallardo J.M., Corrales R.M., Carracedo A. Astrong genetic association between the tumor necrosis factor locus and proliferative vitreoretinopathy: the retina 4 project. Ophthalmology 2010, 117:2417-2423. e2411-2412.
143. Rojas J., Fernandez I., Pastor J.C., Maclaren R.E., Ramkissoon Y., Harsum S., Charteris D.G., Van Meurs J.C., Amarakoon S., Ruiz-Moreno J.M., Rocha-Sousa A., Brion M., Carracedo A. Agenetic case-control study confirms the implication of SMAD7 and TNF locus in the development of proliferative vitreoretinopathy. Investig. Ophthalmol. Vis. Sci. 2013, 54:1665-1678.
144. Rosenkranz S., Kazlauskas A. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 1999, 16:201-216.
145. Rosenkranz S., DeMali K.A., Gelderloos J.A., Bazenet C., Kazlauskas A. Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis. J.Biol. Chem. 1999, 274:28335-28343.
146. Rosenkranz S., Ikuno Y., Leong F.L., Klinghoffer R.A., Miyake S., Band H., Kazlauskas A. Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression. J.Biol. Chem. 2000, 275:9620-9627.
147. Rosenkranz S., Knirel D., Dietrich H., Flesch M., Erdmann E., Bohm M. Inhibition of the PDGF receptor by red wine flavonoids provides a molecular explanation for the "French paradox". FASEB J. 2002, 16:1958-1960.
148. Ryan S.J., Sadda S.R., Hinton D.R. Retina 2012, Saunders. fifth ed.
149. Schwartz S.G., Flynn H.W., Lee W.H., Ssemanda E., Ervin A.M. Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy. Cochrane Database Syst. Rev. 2009, CD006126.
150. Sethi C.S., Lewis G.P., Fisher S.K., Leitner W.P., Mann D.L., Luthert P.J., Charteris D.G. Glial remodeling and neural plasticity in human retinal detachment with proliferative vitreoretinopathy. Investig. Ophthalmol. Vis. Sci. 2005, 46:329-342.
151. Siegbahn A., Johnell M., Nordin A., Aberg M., Velling T. TF/FVIIa transactivate PDGFRbeta to regulate PDGF-BB-induced chemotaxis in different cell types: involvement of Src and PLC. Arterioscler. Thromb. Vasc. Biol. 2008, 28:135-141.
152. Sundaram V., Barsam A., Virgili G. Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Cochrane Database Syst. Rev. 2013, 1:CD006421.
153. Sundaresan M., Yu Z.X., Ferrans V.J., Irani K., Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 1995, 270:296-299.
154. Symeonidis C., Papakonstantinou E., Androudi S., Rotsos T., Diza E., Brazitikos P., Karakiulakis G., Dimitrakos S.A. Interleukin-6 and the matrix metalloproteinase response in the vitreous during proliferative vitreoretinopathy. Cytokine 2011, 54:212-217.
155. Symeonidis C., Papakonstantinou E., Souliou E., Karakiulakis G., Dimitrakos S.A., Diza E. Correlation of matrix metalloproteinase levels with the grade of proliferative vitreoretinopathy in the subretinal fluid and vitreous during rhegmatogenous retinal detachment. Acta Ophthalmol. 2011, 89:339-345.
156. Tamiya S., Liu L., Kaplan H.J. Epithelial-mesenchymal transition and proliferation of retinal pigment epithelial cells initiated upon loss of cell-cell contact. Investig. Ophthalmol. Vis. Sci. 2010, 51:2755-2763.
157. Tanimoto T., Lungu A.O., Berk B.C. Sphingosine 1-phosphate transactivates the platelet-derived growth factor beta receptor and epidermal growth factor receptor in vascular smooth muscle cells. Circ. Res. 2004, 94:1050-1058.
158. Telander D.G., Morales S.A., Mareninov S., Forward K., Gordon L.K. Epithelial membrane protein-2 (EMP2) and experimental proliferative vitreoretinopathy (PVR). Curr. Eye Res. 2011, 36:546-552.
159. Tezel T.H., Kaplan H.J., Del Priore L.V. Fate of human retinal pigment epithelial cells seeded onto layers of human Bruch's membrane. Investig. Ophthalmol. Vis. Sci. 1999, 40:467-476.
160. Tseng W., Cortez R.T., Ramirez G., Stinnett S., Jaffe G.J. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am. J. Ophthalmol. 2004, 137:1105-1115.
161. Tseng J.J., Schiff W.M., Barile G.R., Biscette O., Williams S.L., Cekic O., Dhrami-Gavazi E., Chang S. Influence of postoperative lens status on intraocular pressure in proliferative vitreoretinopathy. Am. J. Ophthalmol. 2009, 147:875-885. 885 e871-872.
162. Umazume K., Liu L., Scott P.A., de Castro J.P., McDonald K., Kaplan H.J., Tamiya S. Inhibition of PVR with a tyrosine kinase inhibitor, dasatinib, in the swine. Investig. Ophthalmol. Vis. Sci. 2013, 54:1150-1159.
163. Ustach C.V., Kim H.R. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol. Cell. Biol. 2005, 25:6279-6288.
164. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E.A. Invivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
165. Velez G., Weingarden A.R., Tucker B.A., Lei H., Kazlauskas A., Young M.J. Retinal pigment epithelium and Muller progenitor cell interaction increase Muller progenitor cell expression of PDGFRalpha and ability to induce proliferative vitreoretinopathy in a rabbit model. Stem Cells Int. 2012, 2012:106486.
166. Velez G., Weingarden A.R., Lei H., Kazlauskas A., Gao G. SU9518 inhibits proliferative vitreoretinopathy in fibroblast and genetically modified Muller cell-induced rabbit models. Investig. Ophthalmol. Vis. Sci. 2013, 54:1392-1397.
167. Vinores S.A., Campochiaro P.A., Conway B.P. Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. Investig. Ophthalmol. Vis. Sci. 1990, 31:14-28.
168. Weller M., Wiedemann P., Heimann K. Proliferative vitreoretinopathy-is it anything more than wound healing at the wrong place?. Int. Ophthalmol. 1990, 14:105-117.
169. Wickham L., Bunce C., Wong D., McGurn D., Charteris D.G. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology 2007, 114:698-704.
170. Wiedemann P., Hilgers R.D., Bauer P., Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am. J. Ophthalmol. 1998, 126:550-559.
171. Williams R.G., Chang S., Comaratta M.R., Simoni G. Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?. Graefes Arch. Clin. Exp. Ophthalmol. 1996, 234:496-503.
172. Yamada H., Tajima S., Nishikawa T., Murad S., Pinnell S.R. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J.Biochem 1994, 116:892-897.
173. Yang C.-M., Olsen K.R., Hernandez E., Cousins S.W. Measurement of cellular proliferation within the vitreous during experimental proliferative vitreoretinopathy. Graefe's Arch. Clin. Exp. Ophthalmol. 1992, 230:66-71.
174. Yang P., Wiser J.L., Peairs J.J., Ebright J.N., Zavodni Z.J., Bowes Rickman C., Jaffe G.J. Human RPE expression of cell survival factors. Investig. Ophthalmol. Vis. Sci. 2005, 46:1755-1764.
175. Yeo J.H., Sadeghi J., Campochiaro P.A., Green W.R., Glaser B.M. Intravitreous fibronectin and platelet-derived growth factor. New model for traction retinal detachment. Arch. Ophthalmol. 1986, 104:417-421.
176. Yokoyama K., Kimoto K., Itoh Y., Nakatsuka K., Matsuo N., Yoshioka H., Kubota T. The PI3K/Akt pathway mediates the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells. Graefes Arch. Clin. Exp. Ophthalmol. 2012, 250:15-23.
177. Zhang N., Peairs J.J., Yang P., Tyrrell J., Roberts J., Kole R., Jaffe G.J. The importance of Bcl-xL in the survival of human RPE cells. Investig. Ophthalmol. Vis. Sci. 2007, 48:3846-3853.
178. Zheng Y., Ikuno Y., Ohj M., Kusaka S., Jiang R., Cekic O., Sawa M., Tano Y. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Jpn. J. Ophthalmol. 2003, 47:158-165.
179. Zhu J., Nguyen D., Ouyang H., Zhang X.H., Chen X.M., Zhang K. Inhibition of RhoA/Rho-kinase pathway suppresses the expression of extracellular matrix induced by CTGF or TGF-beta in ARPE-19. Int. J. Ophthalmol. 2013, 6:8-14.